FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297452659> ?p ?o ?g. }

• W4297452659 endingPage "e41" @default.
• W4297452659 startingPage "e40" @default.
• W4297452659 abstract "<h3>Lead Author's Financial Disclosures</h3> Nothing to disclose. <h3>Study Funding</h3> None. <h3>Background/Synopsis</h3> We present a 47-year-old woman with homozygous familial hypercholesterolemia (HoFH), recurrent ASCVD events, and multiple intolerances to therapy (including lipoprotein apheresis) who was treated successfully with a unique combination of therapeutic plasma exchange (TPE) and pharmacotherapy, including evinacumab. Her treatment with TPE required 1) pre-medication to prevent allergic reactions, 2) use of a specific TPE system selected to reduce risk of allergic reactions, and 3) medical flights bi-monthly across California to perform TPE at our institution. Following initiation of evinacumab, the patient achieved persistent low levels of LDL-C and subsequently discontinued TPE. <h3>Objective/Purpose</h3> To describe the novel use of TPE and evinacumab in HoFH when treatment options are limited. <h3>Methods</h3> Patient consent was obtained. A review of the electronic health records for the patient was completed. <h3>Results</h3> A 47-year-old woman was referred to our Advanced Lipid Disorders Treatment Center for management of HoFH. Genetic testing revealed a heterozygous pathogenic variant in LDLR; however, phenotypically her presentation was consistent with HoFH (initial LDL-C 356 mg/dL, recurrent myocardial infarction, and repeated revascularization starting at age 39 years, and extensive family history of dyslipidemia and early myocardial infarction). The following treatments were attempted: statin therapy (caused intense, intolerable myalgia), lomitapide (caused intractable vomiting and diarrhea), and lipoprotein apheresis (anaphylactoid-like reaction ultimately thought due to ethylene oxide sterilant in the apheresis column and tubing). She tolerated ezetimibe, bempedoic acid, and PCSK9 inhibitor monoclonal antibodies; however, atherogeniclipid-loweringg was insufficient with this regimen (mean+/-SD LDL-C over 1 year: 234.33+/-13.47 mg/dL). Therefore, TPE was initiated with a system that utilizes tubing sterilized via gamma irradiation, however patient still received empiric pretreatment with antihistamines and steroids. This was successful but required the patient to travel by medical flight to receive TPE every 2 weeks. After initiating evinacumab, the patient achieved persistently low LDL-C levels and TPE was successfully discontinued (Figure). <h3>Conclusions</h3> HoFH is a rare genetic disorder that portends high morbidity and early mortality. Patients with HoFH who are intolerant of treatments due to side-effects and allergies represent a unique challenge to the clinical lipid specialist. We present a patient with limited therapeutic options who was responsive to bi-monthly TPE. Similar to what has been observed in clinical trials with lipoprotein apheresis, our patient with HoFH was able to discontinue TPE following initiation of evinacumab. Our patient is tolerating her current therapy, no longer makes bi-monthly medical flights to our center for TPE, and has maintained low levels of atherogenic lipids." @default.
• W4297452659 created "2022-09-29" @default.
• W4297452659 creator A5006497330 @default.
• W4297452659 creator A5037079092 @default.
• W4297452659 creator A5038810249 @default.
• W4297452659 creator A5087918205 @default.
• W4297452659 date "2022-07-01" @default.
• W4297452659 modified "2023-09-27" @default.
• W4297452659 title "Novel Use of Therapeutic Plasma Exchange and Evinacumab in a Patient with Homozygous Familial Hypercholesterolemia" @default.
• W4297452659 doi "https://doi.org/10.1016/j.jacl.2022.05.015" @default.
• W4297452659 hasPublicationYear "2022" @default.
• W4297452659 type Work @default.
• W4297452659 citedByCount "1" @default.
• W4297452659 countsByYear W42974526592022 @default.
• W4297452659 crossrefType "journal-article" @default.
• W4297452659 hasAuthorship W4297452659A5006497330 @default.
• W4297452659 hasAuthorship W4297452659A5037079092 @default.
• W4297452659 hasAuthorship W4297452659A5038810249 @default.
• W4297452659 hasAuthorship W4297452659A5087918205 @default.
• W4297452659 hasConcept C126322002 @default.
• W4297452659 hasConcept C187212893 @default.
• W4297452659 hasConcept C2776738589 @default.
• W4297452659 hasConcept C2778096610 @default.
• W4297452659 hasConcept C2778163477 @default.
• W4297452659 hasConcept C2778751355 @default.
• W4297452659 hasConcept C2779120738 @default.
• W4297452659 hasConcept C2910749824 @default.
• W4297452659 hasConcept C500558357 @default.
• W4297452659 hasConcept C511355011 @default.
• W4297452659 hasConcept C71924100 @default.
• W4297452659 hasConcept C89560881 @default.
• W4297452659 hasConceptScore W4297452659C126322002 @default.
• W4297452659 hasConceptScore W4297452659C187212893 @default.
• W4297452659 hasConceptScore W4297452659C2776738589 @default.
• W4297452659 hasConceptScore W4297452659C2778096610 @default.
• W4297452659 hasConceptScore W4297452659C2778163477 @default.
• W4297452659 hasConceptScore W4297452659C2778751355 @default.
• W4297452659 hasConceptScore W4297452659C2779120738 @default.
• W4297452659 hasConceptScore W4297452659C2910749824 @default.
• W4297452659 hasConceptScore W4297452659C500558357 @default.
• W4297452659 hasConceptScore W4297452659C511355011 @default.
• W4297452659 hasConceptScore W4297452659C71924100 @default.
• W4297452659 hasConceptScore W4297452659C89560881 @default.
• W4297452659 hasIssue "3" @default.
• W4297452659 hasLocation W42974526591 @default.
• W4297452659 hasOpenAccess W4297452659 @default.
• W4297452659 hasPrimaryLocation W42974526591 @default.
• W4297452659 hasRelatedWork W1970086181 @default.
• W4297452659 hasRelatedWork W2022660841 @default.
• W4297452659 hasRelatedWork W2073220867 @default.
• W4297452659 hasRelatedWork W2124843073 @default.
• W4297452659 hasRelatedWork W2444087174 @default.
• W4297452659 hasRelatedWork W2470023540 @default.
• W4297452659 hasRelatedWork W2951800765 @default.
• W4297452659 hasRelatedWork W3138358431 @default.
• W4297452659 hasRelatedWork W4310703711 @default.
• W4297452659 hasRelatedWork W4318055210 @default.
• W4297452659 hasVolume "16" @default.
• W4297452659 isParatext "false" @default.
• W4297452659 isRetracted "false" @default.
• W4297452659 workType "article" @default.